(Total Views: 621)
Posted On: 10/01/2020 11:42:24 AM
Post# of 148908
LOL..I could care less how many "downvotes" I get. That's really sad that so many are more inclined to just put their head in the sand instead of discussing where I may be off the mark. They can push the thumbs down but can't tell me where I am off the mark. If you don't learn from the past, you are doomed to repeat it. My post wasn't a "bash", it was my take at the reality of October 1, 2020. I don't trade in and out- I have a real job that requires me to be hands on with other investments. We'll see how right my take eventually is, but I am looking at it without the blinders and assessing the odds of near-term success. That doesn't mean I'm only looking at this as a near term investment. Far from it. Sitting here with a sizeable bet that we somehow pull through because we have a terrific drug.
Two months ago I stated here that CD12 interim was THE most important milestone for the year, and that grows more true every day. I'm sure that post received some dislikes at the time from folks posting dozens of "potential catalysts" that have gone nowhere or were never real catalysts to begin with. I didn't expect most of them to do much, although I never imagined we would be so far behind on the BLA and only a handful of cancer patients enrolled. Very disappointing on those fronts. Still, all of that can go away in the next two weeks if the drug is indeed a wonder drug for COVID.
Two months ago I stated here that CD12 interim was THE most important milestone for the year, and that grows more true every day. I'm sure that post received some dislikes at the time from folks posting dozens of "potential catalysts" that have gone nowhere or were never real catalysts to begin with. I didn't expect most of them to do much, although I never imagined we would be so far behind on the BLA and only a handful of cancer patients enrolled. Very disappointing on those fronts. Still, all of that can go away in the next two weeks if the drug is indeed a wonder drug for COVID.
(10)
(1)
Scroll down for more posts ▼